5/31/2013

The FDA has accepted BioMarin Pharmaceutical's biologics license application for Vimizim, or BMN-110, elosulfase alfa, an experimental treatment for Mucopolysaccharidosis type IVA, also known as Morquio A
Syndrome. The enzyme replacement therapy was granted a priority-review status.

Full Story:
RTT News

Related Summaries